Rights Issue: Wockhardt will be in focus on March 4

Wockhardt is a global pharmaceutical and biotech company and is India’s leading research-based global healthcare enterprise with relevance in the fields of pharmaceuticals, biotechnology, and a chain of advanced super speciality hospitals.

Wockhardt Limited has informed the bourses that members of the capital raising committee of the Board of Directors of the company, at their latest meeting Thursday, March 3, 2022, interalia, considered and approved the following terms and conditions of the rights issue:

Instrument: Fully paid-up equity shares of face value of Rs 5 each.

Total number of Equity Shares and Rights Issue size: 3,32,44,650 fully paid-up equity shares each for amount aggregating to Rs 748,00,46,250.

Issue Price: Rs 225 per fully paid-up equity share (including a premium of Rs 220 per equity share).

Issue Opening Date: Tuesday, 15th March, 2022

Issue Closing Date: Tuesday, 22nd March, 2022.

Outstanding equity shares prior to the Rights Issue: 11,08,15,503 equity shares.

Outstanding equity shares prior to the Rights Issue:  14,40,60,153 equity shares (assuming full subscription).

Rights Entitlement Ratio: 3:10 (i.e. 3 rights equity shares for every 10 fully paid-up equity shares held by the eligible equity shareholders of the company, as on the record date). If the shareholding of any of the eligible equity shareholder is 4 or more, such shareholders will be entitled to at least 1 equity share.

Record date: Wednesday, March 9, 2022 for the purpose of determining the equity shareholders entitled to receive the rights entitlement in the Rights Issue.

Wockhardt is a global pharmaceutical and biotech company and is India’s leading research-based global healthcare enterprise with relevance in the fields of pharmaceuticals, biotechnology, and a chain of advanced super speciality hospitals.

Investors should keep a close eye on this stock during tomorrow’s trading session!